Target intelligence / Profile preview

T cell receptor beta variable 7-3 (TRBV7-3)

Target
TRBV7-3
Molecular classification
Receptor, Immunoglobulin superfamily, T cell receptor subunit
01

Overview

T cell receptor beta variable 7-3 (TRBV7-3) is a member of the variable domain segment of the beta chain in the human T cell receptor (TCR) complex, which enables antigen recognition by T cells. TRBV7-3 is predicted to be a non-functional open reading frame (ORF)—meaning it is assumed unable to encode a productive TCR beta chain because of genetic alterations at the DNA, RNA, or protein level, which preclude its participation in forming a fully functional TCR complex. In the immune system, productive TCR beta variable segments recombine with other gene segments to generate diversity, allowing T cells to recognize a wide range of peptide-MHC complexes presented on antigen-presenting cells, a process required for adaptive immunity. The TRBV gene cluster, including TRBV7-3, is subject to genetic polymorphism, and some variations have been linked to changes in disease susceptibility, especially in autoimmunity. However, as TRBV7-3 is considered non-functional, there is no known association with therapeutically targeted drugs, biomarkers, or major safety concerns specific to this segment[1][4]. Explanation and context: - TRBV7-3 is not a therapeutically addressed molecular target because it does not encode a functional receptor subunit—it is a “probable non-functional” V region gene segment, sometimes classified as a pseudogene in the context of T cell receptor genetics[1]. - The broader T cell receptor beta chain is critical for T cell activation, signal transduction, and immune response, and alterations in TRBV gene polymorphisms as a group have been tied to autoimmune disease risk[4]. - There is no evidence for drugs directly targeting TRBV7-3 or it being used as a biomarker in clinical settings[1][3][4]. - The gene is sometimes called by multiple synonyms in the literature and genomics resources[1]. If you specifically require information about the general T cell receptor beta chain or functional TRBV segments (rather than this probable non-functional one), those have well-defined roles as immune receptors and can be clinical or therapeutic targets in cancer immunotherapy, autoimmunity, and infection[2][3][4].

Other names
TRBV73TCRBV6S1A1N1TCRBV7S3V segment translation productProbable non-functional T cell receptor beta variable 7-3
02

Biological functions

Immune responseAntigen recognitionSignal transduction (general for T cell receptor family; see explanation)
03

Disease associations

Autoimmune disease (via TRBV polymorphisms)Other (general T cell receptor functions)

Beyond the preview

Go deeper on T cell receptor beta variable 7-3 (TRBV7-3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor beta variable 7-3 (TRBV7-3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call